Libros bestsellers hasta 50% dcto  Ver más

menú

0
  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional
portada Emerging Drugs and Targets for Alzheimer's Disease: Volume 1: Beta-Amyloid (Drug Discovery) (en Inglés)
Formato
Libro Físico
Año
2010
Idioma
Inglés
N° páginas
342
Encuadernación
Tapa Dura
ISBN13
9781849730631
N° edición
1

Emerging Drugs and Targets for Alzheimer's Disease: Volume 1: Beta-Amyloid (Drug Discovery) (en Inglés)

Ana Martinez (Autor) · Royal Society Of Chemistry · Tapa Dura

Emerging Drugs and Targets for Alzheimer's Disease: Volume 1: Beta-Amyloid (Drug Discovery) (en Inglés) - ana martinez

Libro Físico

$ 181.63

$ 203.00

Ahorras: $ 21.37

11% descuento
  • Estado: Nuevo
Se enviará desde nuestra bodega entre el Viernes 31 de Mayo y el Lunes 03 de Junio.
Lo recibirás en cualquier lugar de Estados Unidos entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Emerging Drugs and Targets for Alzheimer's Disease: Volume 1: Beta-Amyloid (Drug Discovery) (en Inglés)"

Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts, these volumes are an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field.

Opiniones del libro

Ver más opiniones de clientes
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Preguntas frecuentes sobre el libro

Todos los libros de nuestro catálogo son Originales.
El libro está escrito en Inglés.
La encuadernación de esta edición es Tapa Dura.

Preguntas y respuestas sobre el libro

¿Tienes una pregunta sobre el libro? Inicia sesión para poder agregar tu propia pregunta.

Opiniones sobre Buscalibre

Ver más opiniones de clientes